Ilmarinen Mutual Pension Insurance Co Takes Position in argenex SE $ARGX

Ilmarinen Mutual Pension Insurance Co bought a new stake in shares of argenex SE (NASDAQ:ARGX) during the 4th quarter, HoldingsChannel.com reports. The firm bought 3,600 shares of the company’s stock, valued at approximately $3,027,000.

Several other institutional investors have also made changes to their positions in the business. Abound Wealth Management boosted its stake in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in argenex in the 4th quarter valued at $28,000. Ameriflex Group Inc. acquired a new stake in argenex in the 3rd quarter valued at $32,000. Aventura Private Wealth LLC acquired a new stake in argenex in the 4th quarter valued at $38,000. Finally, Sunbelt Securities Inc. acquired a new stake in argenex in the 3rd quarter valued at $36,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARGX has been the topic of several recent analyst reports. Robert W. Baird boosted their price target on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Citizens Jmp boosted their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Guggenheim boosted their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Stock Performance

argenex stock opened at $835.99 on Friday. The firm has a market cap of $51.99 billion, a P/E ratio of 37.22, a P/E/G ratio of 1.33 and a beta of 0.46. The business’s fifty day moving average is $779.30 and its two-hundred day moving average is $815.27. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, equities research analysts predict that argenex SE will post 25.27 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.